Tumor Necrosis Factor News and Research

RSS

Cornell biomedical engineers identify new way to destroy metastasizing cancer cells

Cornell biomedical engineers have discovered a new way to destroy metastasizing cancer cells traveling through the bloodstream - lethal invaders that are linked to almost all cancer deaths - by hitching cancer-killing proteins along for a ride on life-saving white blood cells.

8 Jan 2014

Elevated BACE1 activity in mild cognitive impairment could be early indicator of AD, says study

The critical enzyme beta-secretase1 (BACE1) is known to be elevated in brains with sporadic Alzheimer disease (AD). Scientists have now found increased levels of BACE1 in brains with mild cognitive impairment (MCI), suggesting that BACE1 activity is important for conversion of mild cognitive impairment to AD and may be an early indicator of AD.

12 Dec 2013

Scientists discover how lymphotoxin controls production of immunoglobulins in gut

Lymphotoxin is a cytokine, or intercellular messenger, and plays an important role in the immunological balance of the gastrointestinal tract. It regulates the immune system of the digestive tract, which is made up of immune cells, immunoglobulins (antibodies) as well as intestinal bacteria.

10 Dec 2013

FDA advisory committee backs Takeda's vedolizumab for treatment of ulcerative colitis, Crohn's disease

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced that a joint panel of members from the Gastrointestinal Drugs and Drug Safety and Risk Management Advisory Committees of the United States Food and Drug Administration voted to recommend approval of Takeda's vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease.

9 Dec 2013

Type 2 diabetes cytokine elevation places teeth at risk

Scientists have detected significant differences in the cytokine and chemokine make up of gingival crevicular fluid taken from chronic periodontitis patients with uncontrolled Type 2 diabetes and those without.

21 Nov 2013

Women taking immunosuppressive medications during pregnancy do not put their babies at risk

Women with chronic autoimmune diseases who take immunosuppressive medications during their first trimester of pregnancy are not putting their babies at significantly increased risk of adverse outcomes, according to a Vanderbilt study released online by the journal Arthritis and Rheumatism.

11 Nov 2013

TGen-led study reveals viable target to prevent spread of brain cancer

A cellular pathway interaction known as TWEAK-Fn14, often associated with repair of acute injuries, also is a viable target for drug therapy that could prevent the spread of cancer, especially brain cancer, according to a study led by the Translational Genomics Research Institute.

11 Nov 2013

EKF Diagnostics to introduce upgraded POC analyzer and new sTNFr1 test kit at Medica 2013

EKF, announces it will be premiering two novel diagnostic tests at Medica 2013, 20th to 23rd November, Düsseldorf, Germany.

From EKF Diagnostics 8 Nov 2013

Phase 3 study shows STELARA inhibits structural damage in patients with active psoriatic arthritis

New findings from two integrated Phase 3 Janssen Research & Development, LLC (Janssen)-sponsored studies showed treatment with STELARA- (ustekinumab) resulted in significantly greater inhibition of structural damage in patients with active psoriatic arthritis compared with placebo.

29 Oct 2013

Combination of three DMARDs more cost-effective in treating early rheumatoid arthritis

Starting with a combination of three traditional disease-modifying antirheumatic drugs (called DMARDs) for treating early rheumatoid arthritis is more cost-effective long term, with comparable benefits, than using either an immediate or step-up approach with anti-tumor necrosis factor (called Anti-TNFs) drugs and methotrexate, according to new research findings presented this week at the American College of Rheumatology Annual Meeting in San Diego.

28 Oct 2013

Anti-tumor necrosis factor drugs modestly reduce risk of acute coronary syndrome

Tumor necrosis factor inhibitor drugs (commonly called Anti-TNFs) modestly reduce the risk of acute coronary syndrome, such as heart attacks and angina, in rheumatoid arthritis patients whose inflammation places them at higher risk of developing coronary heart disease, according to new research findings presented this week at the American College of Rheumatology Annual Meeting in San Diego.

28 Oct 2013

Two aggressive therapy approaches effective for children with juvenile idiopathic arthritis

Children with juvenile idiopathic arthritis who receive early, aggressive therapy with a combination of medications achieve clinical inactive disease status faster than they would with less aggressive therapy, according to new research presented this week at the American College of Rheumatology Annual Meeting in San Diego.

28 Oct 2013

Gene variations in response to injury can impact clinical outcomes in TBI

Subtle variations in genes that regulate a person's inflammatory response to injury can impact clinical outcomes in TBI, according to a new study published in Journal of Neurotrauma.

18 Oct 2013

Finding highlights new ways of treating inflammation disorders

A team led by scientists at The Scripps Research Institute (TSRI) has identified key signaling proteins in the inflammation process that contribute to the development of inflammatory diseases such as rheumatoid arthritis, psoriasis, sepsis and inflammatory bowel diseases.

11 Oct 2013

Anti-inflammatory mechanism leads to development of oral medications for atherosclerosis, IBS

Research led by Charles Nichols, PhD, Associate Professor of Pharmacology at LSU Health Sciences Center New Orleans, describes a powerful new anti-inflammatory mechanism that could lead to the development of new oral medications for atherosclerosis and inflammatory bowel disorders (IBS).

7 Oct 2013

ACR journals publish guide that provides new treatments for children with systemic JIA

In the U.S., there are nearly 300,000 children with juvenile arthritis and other rheumatic illnesses according to estimates from the American College of Rheumatology (ACR). For pediatric patients with systemic juvenile idiopathic arthritis (JIA), effective treatment for this disabling disease is imperative.

24 Sep 2013

FDA approves STELARA (Ustekinumab) for treatment of active psoriatic arthritis

Janssen Biotech, Inc., announced today that the U.S. Food and Drug Administration (FDA) has approved STELARA® (ustekinumab) alone or in combination with methotrexate for the treatment of adult patients (18 years or older) with active psoriatic arthritis.

23 Sep 2013

GSK Returns Vercirnon Rights To Chemocentryx After Phase III Flop

...

19 Sep 2013

GSK Returns Vercirnon Rights To Chemocentryx After Phase III Flop

...

18 Sep 2013

FDA grants Priority Review status to Takeda's investigational drug vedolizumab for ulcerative colitis

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced that the United States Food and Drug Administration has granted Priority Review status for the Biologics License Application for its new investigational drug vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis.

5 Sep 2013

Tumor Necrosis Factor News and Research

Cornell biomedical engineers identify new way to destroy metastasizing cancer cells

Elevated BACE1 activity in mild cognitive impairment could be early indicator of AD, says study

Scientists discover how lymphotoxin controls production of immunoglobulins in gut

FDA advisory committee backs Takeda's vedolizumab for treatment of ulcerative colitis, Crohn's disease

Type 2 diabetes cytokine elevation places teeth at risk

Women taking immunosuppressive medications during pregnancy do not put their babies at risk

TGen-led study reveals viable target to prevent spread of brain cancer

EKF Diagnostics to introduce upgraded POC analyzer and new sTNFr1 test kit at Medica 2013

Phase 3 study shows STELARA inhibits structural damage in patients with active psoriatic arthritis

Combination of three DMARDs more cost-effective in treating early rheumatoid arthritis

Anti-tumor necrosis factor drugs modestly reduce risk of acute coronary syndrome

Two aggressive therapy approaches effective for children with juvenile idiopathic arthritis

Gene variations in response to injury can impact clinical outcomes in TBI

Finding highlights new ways of treating inflammation disorders

Anti-inflammatory mechanism leads to development of oral medications for atherosclerosis, IBS

ACR journals publish guide that provides new treatments for children with systemic JIA

FDA approves STELARA (Ustekinumab) for treatment of active psoriatic arthritis

GSK Returns Vercirnon Rights To Chemocentryx After Phase III Flop

GSK Returns Vercirnon Rights To Chemocentryx After Phase III Flop

FDA grants Priority Review status to Takeda's investigational drug vedolizumab for ulcerative colitis

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News